AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05016973
Drug: Triplizumab
RxNorm normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg, Intravenous drip on days 1 every 21 days
Trial: NCT02772120
Drug: Vaginal progesterone gel (Crinone® 8%)
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
Trial: NCT02772120
Drug: Intramuscular Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
Trial: NCT06268093
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 50 - 200 mg once at nightime
Trial: NCT05264077
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
Trial: NCT05631886
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous abraxane 125 mg/m\^2/day on day-5.
Trial: NCT05631886
Drug: anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anti-PD-1 antibody 200 mg/day.
Trial: NCT05631886
Drug: Anti-CTLA4 Monoclonal Antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous anti-CTLA4 antibody 1 mg/kg/day
Trial: NCT06318546
Drug: Dexmedetomidine Injection [Precedex],,,
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
Trial: NCT04642430
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Refer to Apixaban group
Trial: NCT04642430
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Refer to Rivaroxaban group
Trial: NCT05700617
Drug: 1:1 Randomization to receive milrinone or dobutamine
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized to receive either inotropic agent: milrinone or dobutamine
Trial: NCT05700617
Drug: 1:1 Randomization to receive dobutamine or milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized to receive either inotropic agent: milrinone or dobutamine
Trial: NCT05849246
Drug: Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®
Trial: NCT05849246
Drug: Sintilimab+Carboplatin or Cisplatin+Pemetrexed
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Trial: NCT05849246
Drug: Tusamitamab ravtansine+Sintilimab
RxNorm normalized name: mirvetuximab soravtansine
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®
Trial: NCT04724252
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
Trial: NCT04287829
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infusion
Trial: NCT04287829
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsule
Trial: NCT04876391
Drug: Spesolimab
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab
Trial: NCT06332755
Drug: LB-LR1109
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT05430919
Drug: REGN5713
RxNorm normalized name: Immunoglobulin G4 [224-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulfide with human monoclonal REGN5713 κ-chain, dimer
DrugBank: Bremzalerbart (DB19417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT05503147
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
Trial: NCT06494644
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
Trial: NCT06494644
Drug: AZD6793+ Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
Trial: NCT05888233
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
Trial: NCT04755387
Drug: Ticagrelor 90mg
RxNorm normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.
Trial: NCT04755387
Drug: Ticagrelor 60/45mg
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.
Trial: NCT04899414
Drug: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
Trial: NCT05531942
Drug: Ginkgo Diterpene Lactone Meglumine Injection
RxNorm normalized name: citronellene lactone
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
Trial: NCT06498531
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
Trial: NCT05323734
Drug: Ganaxalone
RxNorm normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GNX will be administered
Trial: NCT06302621
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
Trial: NCT06302621
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
Trial: NCT05593770
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Trial: NCT06540209
Drug: Bacillus clausii
RxNorm normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will be give Bacillus clausii for 5 days
Trial: NCT05289908
Drug: Pemetrexed (1)
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
Trial: NCT05289908
Drug: Pemetrexed (2)
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
Trial: NCT05289908
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
Trial: NCT05289908
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Trial: NCT06296706
Drug: Docetaxel for injection (Albumin-bound)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
Trial: NCT06296706
Drug: Taxotere (docetaxel)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxotere, by intravenous infusion, every 3 weeks.
Trial: NCT06540209
Drug: ORS
RxNorm normalized name: HORSE
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS will be given to all children for 5 days
Trial: NCT06641453
Drug: Fludarabine Phosphate for Injection
RxNorm normalized name: Fludarabine Phosphate for Injection
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
Trial: NCT06641453
Drug: Cyclophosphamide for Injection
RxNorm normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
Trial: NCT04858997
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Trial: NCT04858997
Drug: AI
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI, orally once daily (continuously)
Trial: NCT06475820
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day.
Trial: NCT05024214
Drug: Lenvatinib + Envafolimab
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.
Trial: NCT05024214
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
Trial: NCT06407232
Drug: Letermovir
RxNorm normalized name: Letermovir
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 480 mg taken orally once daily, for 84 days
Trial: NCT05634460
Drug: potassium hydroxide
RxNorm normalized name: Potassium Hydroxide
DrugBank: Potassium hydroxide (DB11153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
Trial: NCT06446648
Drug: ICG
RxNorm normalized name: ICG136
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
Trial: NCT05003700
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg once daily (QD) oral dosing.
Trial: NCT05003700
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 3 weeks.
Trial: NCT05145816
Drug: Belantamab mafodotin 2.5 mg/kg (8 weeks)
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
Trial: NCT05145816
Drug: Belantamab mafodotin 1.9 mg/kg (8 weeks)
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
Trial: NCT05145816
Drug: Belantamab mafodotin 1.4 mg/kg (12 weeks)
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Trial: NCT05145816
Drug: Belantamab mafodotin 1.9 mg/kg (12 weeks)
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Trial: NCT05145816
Drug: Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
Trial: NCT05145816
Drug: Belantamab mafodotin 1.0 mg/kg (12 weeks)
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Trial: NCT06673238
Drug: ABBV-722
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06672133
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given：IV
Trial: NCT06520553
Drug: BI 1569912 (C-14)
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unlabelled BI 1569912 mixed with \[14C\]- labelled BI 1569912
Trial: NCT06520553
Drug: BI 1569912 (C-13)
RxNorm normalized name: Urea C 13
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: \[13C\]- labelled BI 1569912
Trial: NCT06689241
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg
Trial: NCT06689241
Drug: rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg
Trial: NCT06686108
Drug: Azacitidine (AZA) Days 1 - 5
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle
Trial: NCT06686108
Drug: Decitabine (DAC)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.
Trial: NCT06686108
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: venetoclax, 400mg/d, days 1-7 of each 28-day cycle
Trial: NCT05691361
Drug: ADX-324
RxNorm normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siRNA duplex oligonucleotide
Trial: NCT05347641
Drug: Penpulimab
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5
Trial: NCT06209372
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
DrugBank: Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (DB10799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol infusion
Trial: NCT04775979
Drug: diphenylcyclopropenone (DPCP)
RxNorm normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depigmenting agent
Trial: NCT05157997
Drug: Casirivimab and Imdevimab Antibody Cocktail
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
Trial: NCT06124924
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
Trial: NCT04565301
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adductor canal block
Trial: NCT04565301
Drug: neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adductor canal block
Trial: NCT06543069
Drug: Sintilimab, Bevacizumab , Pemetrexed , Cisplatin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
Trial: NCT00000690
Drug: Dextran sulfate
RxNorm normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06312787
Drug: VX-118
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and Suspension for Oral Administration
Trial: NCT06075277
Drug: BI 1810631
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1810631
Trial: NCT05101551
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19
Trial: NCT05101551
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5